Viral infections pose a threat to patients receiving allogeneic transplants because of the immunosuppressive drug regimens used to prevent graft rejection. For this reason alternative schemes involving the induction of immunological tolerance have been developed as an alternative strategy to selectively but not globally tolerize a patient. We have developed both peripheral and central tolerization regimens in mice using antibody (anti-CD1 54) approaches that are successful in establishing long term tolerance to allogeneic grafts. These mice can maintain their grafts and eventually effectively control virus infections. However, in the first few weeks after tolerization, these mice and their grafts are vulnerable to infection, and we propose the following specific aims to understand how infections with several experimental viruses, including lymphocytic choriomeningitis virus (LCMV), Pichinde virus (PV), vaccinia virus (VV), murine cytomegalovirus (MCMV), and influenza A virus IAV), can disrupt the maintenance of transplantation tolerance during this vulnerable period. With Project 1 we are also developing additional CD154 RNA knock down approaches to tolerize mice. The overall hypotheses to be supported or refuted in this Project 2 are that heterologous cross-reactive immunity, as opposed to bystander activation, is responsible forthe virus-induced abrogation ofthe maintenance of peripheral tolerance, that T regulatory cells may modulate this process, and that viruses are threats to centrally tolerized hosts and the maintenance of their grafts.

Public Health Relevance

It is well-documented that viral infections are major threats to the survival of grafts of transplant patients and that immunosuppressive drug therapy given to prevent graft rejection makes patients susceptible to such infections. This was recently illustrated in the deaths of transplantation patients receiving grafts from a patient unknowingly infected with LCMV. Here we examine alternative tolerization schemes and how these grafts are impacted by viral infections.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-PTM-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
United States
Zip Code
Negrin, Kimberly A; Roth Flach, Rachel J; DiStefano, Marina T et al. (2014) IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One 9:e107265
Brehm, Michael A; Wiles, Michael V; Greiner, Dale L et al. (2014) Generation of improved humanized mouse models for human infectious diseases. J Immunol Methods 410:3-17
Amano, Shinya U; Cohen, Jessica L; Vangala, Pranitha et al. (2014) Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metab 19:162-71
Daniels, Keith A; Hatfield, Steven D; Welsh, Raymond M et al. (2014) MHC basis of T cell-dependent heterologous immunity to arenaviruses. Virology 464-465:213-7
Jurczyk, Agata; Bortell, Rita; Alonso, Laura C (2014) Human ?-cell regeneration: progress, hurdles, and controversy. Curr Opin Endocrinol Diabetes Obes 21:102-8
Aouadi, Myriam; Vangala, Pranitha; Yawe, Joseph C et al. (2014) Lipid storage by adipose tissue macrophages regulates systemic glucose tolerance. Am J Physiol Endocrinol Metab 307:E374-83
Aryee, Ken-Edwin; Shultz, Leonard D; Brehm, Michael A (2014) Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development. Methods Mol Biol 1185:267-78
Urban, Stina L; Welsh, Raymond M (2014) Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses. PLoS Pathog 10:e1004357
Maykel, Justin; Liu, Jian Hua; Li, Hanchen et al. (2014) NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer. Dig Dis Sci 59:1169-79
Sabio, Guadalupe; Davis, Roger J (2014) TNF and MAP kinase signalling pathways. Semin Immunol 26:237-45

Showing the most recent 10 out of 81 publications